title: Effect of naftopidil on urethral obstruction in benign prostatic hyperplasia: assessment by urodynamic studies.
abstract: Thirty-two patients with voiding dysfunction attributable to symptomatic benign prostatic hyperplasia were treated with naftopidil, an alpha 1-blocker, at doses of 25-75 mg/day for 4-6 weeks. The efficacy of the drug was assessed from the changes in urinary symptoms and urodynamic data. Total symptom scores were significantly reduced after treatment (P < 0.001). Average flow rate and maximum flow rate were significantly increased (P < 0.001 and P < 0.001, respectively), and residual urine volume, residual urine rate (ratio of residual urine volume/sum of voided volume and residual urine volume), and maximum urethral closure pressure were significantly (P < 0.05, P < 0.01, and P < 0.05, respectively) reduced, and at bladder capacity, the first desire to void was significantly (P < 0.05) increased. The pressure/flow study demonstrated no changes in intravesical pressure at maximum flow, but a significant (P < 0.05) reduction in minimum urethral resistance. A mild side effect (dizziness) was noted in one patient (3.3%), which soon disappeared after the dose was decreased. The efficacy was good or excellent in 21 of 30 patients (70.0%). The drug was evaluated to be promising in the treatment of bladder outlet obstruction due to benign prostatic hyperplasia.
authors.affiliation: Department of Urology, School of Medicine, Chiba University, Japan.
authors.forename: K
authors.initials: K
authors.lastname: Yasuda
authors.forename: T
authors.initials: T
authors.lastname: Yamanishi
authors.forename: M
authors.initials: M
authors.lastname: Tojo
authors.forename: K
authors.initials: K
authors.lastname: Nagashima
authors.forename: S
authors.initials: S
authors.lastname: Akimoto
authors.forename: J
authors.initials: J
authors.lastname: Shimazaki
mesh_terms: D000317:Adrenergic alpha-Antagonists / Q000627:therapeutic use*; D000368:Aged; D006801:Humans; D008297:Male; D008875:Middle Aged; D009281:Naphthalenes / Q000627:therapeutic use*; D010879:Piperazines / Q000627:therapeutic use*; D011470:Prostatic Hyperplasia / Q000150:complications* / Q000503:physiopathology; D016896:Treatment Outcome; D014524:Urethral Obstruction / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D014556:Urine; D014563:Urodynamics / Q000187:drug effects*
chemical_list: D000317:Adrenergic alpha-Antagonists; D009281:Naphthalenes; D010879:Piperazines; C064357:naftopidil